CAS NO: | 1622849-43-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | GSK3145095 is aRIP1 kinaseinhibitor with anIC50of 6.3 nM[1]. | ||||||||||||||||
IC50& Target | IC50: 6.3 nM (RIP1 kinase )[1] | ||||||||||||||||
体外研究 (In Vitro) | GSK3145095 potently blocks the TNF response as shown by determination of overall cell viability as measured by cellular ATP levels (IC50= 1.6 nM), cell death as measured by LDH release (IC50= 0.5 nM) and RIP1-dependent inflammatory cytokine MIP-1β production, either as absolute levels for protein, or fold changes in mRNA expression (IC50= 0.4 nM)[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 397.38 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H17F2N5O2 | ||||||||||||||||
CAS 号 | 1622849-43-7 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 250 mg/mL(629.12 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|